Experimental Peptide Quiets Chronic Pain Signals While Preserving Protective Pain
Inside Precision Medicine7 Oct · 07:24← All topics · now
Development ↘
Development ↘
Development ↘
Development ↘
Development ↘
Development ↘
Right now
A review is mapping molecular stages, risk factors and emerging treatments for diabetic nerve pain.
8 reports · the last 24 hours
Summary · from headlines4 points
- A promising nonopioid approach to reducing neuropathic pain disrupts a protein interaction.
- A new antibody silences nerve pain for days without blocking normal pain.
- Researchers report an intracellular circuit responsible for chronic pain; blocking a nerve protein could interrupt it.
- An experimental peptide quiets chronic pain signals while preserving protective pain.
Latest developments6 to read first
Diabetic peripheral neuropathy: Molecular staging, risk factors, therapeutics, and emerging trends
EurekAlert! Science News Releases7 Oct · 07:24BU researchers discover intracellular circuit responsible for chronic pain
EurekAlert! Science News Releases7 Oct · 04:04Blocking a nerve protein could interrupt chronic pain rather than simply mask it
Medical Xpress7 Oct · 03:34Biotech’s peptide shows promise as ‘bait molecule’ to treat neuropathic pain in mice
Fierce Biotech7 Oct · 02:54New Antibody Treatment Silences Nerve Pain for Days Without Blocking Normal Pain
SciTechDaily7 Oct · 02:54Timeline 8 reports
7 Oct 20267 reportsToday
07:002 reports
06:00nothing heard
05:00nothing heard
04:001 report
03:001 report
02:003 reports
6 Oct 20261 report
23:001 report
← All topics · nowOne topic